Assuntos
Suplementos Nutricionais/efeitos adversos , Eritromelalgia/etiologia , Febre/induzido quimicamente , Ácido Hidroxi-Indolacético/urina , Triptofano/administração & dosagem , Adulto , Eritromelalgia/diagnóstico , Febre/fisiopatologia , Seguimentos , Pé , Mãos , Humanos , Masculino , Periodicidade , Remissão Espontânea , Medição de Risco , Termografia/métodosRESUMO
INTRODUCTION: Postmenopausal women manifest emotional disorders associated with an increase in appetite. The aim of the study was to assess the serotonin and melatonin secretion and metabolism in postmenopausal women in relation to eating disorders. MATERIAL AND METHODS: Sixty postmenopausal women and 30 women without hormonal disturbances were enrolled into the study and divided into three groups: group I (control) - women without menstrual disorders, group II - postmenopausal women without appetite disorders and change in body weight, and group III - postmenopausal women with increased appetite and weight gain. Serum melatonin, serotonin, urinary 6-sulfatoxymelatonin (aMT6s), and 5-hydroxyindoleacetic acid (5-HIAA) excretion were measured. RESULTS: Serum serotonin and melatonin levels in groups II and III were lower compared to group I. Urinary 5-HIAA and aMT6s excretion was lower in overweight women. In group III the correlation between the serum level of serotonin, melatonin, and BMI was negative; a high statistical significance was found between BMI and urinary aMT6s excretion. CONCLUSIONS: Melatonin supplementation and use of drugs modulating the serotonin homeostasis together with female hormones have a beneficial effect in complex treatment of disorders of eating in postmenopausal women. (Endokrynol Pol 2016; 67 (3): 299-304).
Assuntos
Transtornos da Alimentação e da Ingestão de Alimentos/fisiopatologia , Melatonina/metabolismo , Pós-Menopausa , Serotonina/metabolismo , Adulto , Transtornos da Alimentação e da Ingestão de Alimentos/sangue , Transtornos da Alimentação e da Ingestão de Alimentos/metabolismo , Transtornos da Alimentação e da Ingestão de Alimentos/urina , Feminino , Humanos , Ácido Hidroxi-Indolacético/urina , Melatonina/análogos & derivados , Melatonina/sangue , Melatonina/urina , Pessoa de Meia-Idade , Serotonina/sangueRESUMO
The management of overweight may include the use of dietary supplements targeted to counter the feeling of hunger. A randomized, double-blind, placebo-controlled trial has been performed in 20 overweight females. These subjects were randomly assigned to supplement their diet with either an extract from Griffonia Simplicifolia (10 subjects) or a placebo (10 matched subjects) for 4-weeks, in conjunction with a personalised reduced calorie diet. The main aim of this study was to evaluate the efficacy, by the assessment of 24-h urinary 5-hydroxyindoleacetic acid levels (5-HIAA), of 1-month administration of a dietary supplement containing 5-hydroxytryptophan (5-HTP) from botanical extracts in healthy, overweight females. Secondary endpoints were the assessment of sensation of appetite (by Haber score), body composition, and severity of binge eating. The supplemented group had a significant increase of 24-h urinary 5-HIAA levels (p<0.001), and a decrease in Haber score (p<0.001) while the placebo group did not show significant changes. With regard to changes in body composition, statistically significant differences between the treatment groups were found for the mean change in BMI, suprailiac skinfold thicknesses, arm circumference and hip circumference. Other parameters were found to be similar in the treated and in the placebo groups. In conclusion, this study shows that the 5-hydroxytryptophan present in the Griffonia extract, administered via spray to the oral cavity, is adequately absorbed, as confirmed by the increase in 24-h urinary 5-HIAA, and that the supplementation of the diet of overweight women with 5-hydroxytryptophan increases the feeling of satiety associated with a decrease in BMI.
Assuntos
5-Hidroxitriptofano/farmacocinética , Antidepressivos de Segunda Geração/uso terapêutico , Dieta Redutora , Griffonia , Fome/efeitos dos fármacos , Sobrepeso/tratamento farmacológico , Fitoterapia , Extratos Vegetais/farmacocinética , Saciação/efeitos dos fármacos , 5-Hidroxitriptofano/uso terapêutico , Adolescente , Adulto , Índice de Massa Corporal , Método Duplo-Cego , Feminino , Humanos , Ácido Hidroxi-Indolacético/urina , Pessoa de Meia-Idade , Sprays Orais , Sobrepeso/dietoterapia , Extratos Vegetais/uso terapêutico , Resultado do TratamentoRESUMO
OBJECTIVES: To determine the effect of acupuncture on hot flash frequency and intensity, quality of life, and sleep quality in patients undergoing hormonal therapy for prostate cancer. Hot flashes are a common adverse effect of hormonal therapy for prostate cancer. METHODS: Men who had a hot flash score > 4 who were receiving androgen deprivation therapy for prostate cancer underwent acupuncture with electrostimulation biweekly for 4 weeks, then weekly for 6 weeks, using a predefined treatment plan. The primary endpoint was a 50% reduction in the hot flash score after 4 weeks of therapy, calculated from the patients' daily hot flash diaries. The hot flash-related quality of life and sleep quality and biomarkers potentially related to hot flashes, including serotonin, calcitonin gene-related peptide, and urinary 5-hydroxyindoleacetic acid, were examined. RESULTS: A total of 25 men were enrolled from September 2003 to April 2007. Of these, 22 were eligible and evaluable. After 4 weeks, 9 (41%, 95% confidence interval 21%-64%) of 22 patients had had a > 50% reduction in the hot flash score. Of the 22 patients, 12 (55%, 95% confidence interval 32%-76%) met this response definition at any point during the therapy course. No patient had a significant increase in hot flash score during therapy. A reduced hot flash score was associated with improvement in the hot flash-related quality of life and sleep quality. CONCLUSIONS: Multiple placebo-controlled trials have demonstrated a 25% response rate to placebo treatment for hot flashes. Of the 22 patients, 41% had responded by week 4 and 55% overall in the present pilot study, providing evidence of a potentially meaningful benefit. Additional studies of acupuncture for hot flashes in this population are warranted.
Assuntos
Terapia por Acupuntura , Antagonistas de Androgênios/uso terapêutico , Fogachos/terapia , Neoplasias da Próstata/terapia , Idoso , Idoso de 80 Anos ou mais , Antagonistas de Androgênios/efeitos adversos , Peptídeo Relacionado com Gene de Calcitonina/sangue , Fogachos/etiologia , Fogachos/metabolismo , Humanos , Ácido Hidroxi-Indolacético/urina , Masculino , Pessoa de Meia-Idade , Orquiectomia , Qualidade de Vida , Serotonina/sangueAssuntos
5-Hidroxitriptofano/efeitos adversos , Antidepressivos de Segunda Geração/efeitos adversos , Ácido Hidroxi-Indolacético/urina , Fitoterapia/efeitos adversos , 5-Hidroxitriptofano/administração & dosagem , Antidepressivos de Segunda Geração/administração & dosagem , Diarreia/induzido quimicamente , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
This study analyzed indicators of alcohol-related problems in opiate addicts before, during, and after leaving methadone maintenance treatment (MMT), in relation to illicit drug use and retention in treatment. The study was based on 204 patients, admitted to MMT for the first time between 1 January 1995 and 31 July 2000, and followed until 31 December 2000. Three measures were used to indicate alcohol use and alcohol-related problems; records of hospital care with an alcohol-related diagnosis, any treatment with alcohol-sensitizing drugs (disulfiram or calcium carbimide) during MMT, and results of the 5-hydroxytryptophol to 5-hydroxyindoleacetic acid ratio (5HTOL/5HIAA) in urine, a sensitive biomarker for recent drinking. Use of illicit drugs was determined by routine urine drug testing. About one third of the patients (n = 69) had a lifetime prevalence of hospital treatment for an alcohol-related diagnosis, 45 of whom had been hospitalized (mean 4.2 stays) prior to the start of MMT. There was a significant association (p<0.05) between the number of alcohol-related diagnoses prior to treatment and a positive 5HTOL/5HIAA test during MMT. The alcohol indicators first became positive on average 1.6 years after admission to treatment, compared with after about 4 months for illicit drugs. Use of cannabis or benzodiazepines was significantly associated with alcohol use. Female methadone patients with indications of alcohol-related problems relapsed more often into illicit drug use than did women without such indications (3.9 vs. 2.5 relapse periods/year; p<0.005), whereas no significant association was found for men. The results of the present study indicate that drinking problems among patients undergoing MMT is associated with an increased risk of relapse into illicit drug use and with discharge from treatment. Concurrent treatment of alcohol-related problems, including systematic monitoring of alcohol use, therefore should be recommended to reduce the risk for relapse into illicit drug use and improve overall treatment outcome in MMT.
Assuntos
Alcoolismo/epidemiologia , Metadona/uso terapêutico , Entorpecentes/uso terapêutico , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Abuso de Substâncias por Via Intravenosa/epidemiologia , Adulto , Dissuasores de Álcool/efeitos adversos , Dissuasores de Álcool/uso terapêutico , Alcoolismo/psicologia , Alcoolismo/reabilitação , Comorbidade , Cianamida/efeitos adversos , Cianamida/uso terapêutico , Dissulfiram/efeitos adversos , Dissulfiram/uso terapêutico , Feminino , Seguimentos , Humanos , Ácido Hidroxi-Indolacético/urina , Hidroxitriptofol/urina , Drogas Ilícitas/urina , Masculino , Transtornos Relacionados ao Uso de Opioides/psicologia , Transtornos Relacionados ao Uso de Opioides/reabilitação , Pacientes Desistentes do Tratamento/psicologia , Readmissão do Paciente/estatística & dados numéricos , Recidiva , Risco , Fatores Sexuais , Detecção do Abuso de Substâncias , Abuso de Substâncias por Via Intravenosa/psicologia , Abuso de Substâncias por Via Intravenosa/reabilitação , SuéciaRESUMO
Women diagnosed with breast cancer received massage therapy or practiced progressive muscle relaxation (PMR) for 30-min sessions 3 times a week for 5 weeks or received standard treatment. The massage therapy and relaxation groups reported less depressed mood, anxiety, and pain immediately after their first and last sessions. By the end of the study, however, only the massage therapy group reported being less depressed and less angry and having more vigor. Dopamine levels, Natural Killer cells, and lymphocytes also increased from the first to the last day of the study for the massage therapy group. These findings highlight the benefit of these complementary therapies, most particularly massage therapy, for women with breast cancer.
Assuntos
Neoplasias da Mama/imunologia , Neoplasias da Mama/psicologia , Depressão/imunologia , Depressão/terapia , Células Matadoras Naturais/citologia , Massagem , Adulto , Ira , Ansiedade/imunologia , Ansiedade/psicologia , Ansiedade/terapia , Depressão/psicologia , Dopamina/sangue , Dopamina/urina , Feminino , Humanos , Ácido Hidroxi-Indolacético/sangue , Ácido Hidroxi-Indolacético/urina , Contagem de Linfócitos , Pessoa de Meia-Idade , Dor/imunologia , Dor/psicologia , Manejo da Dor , Terapia de RelaxamentoRESUMO
AIMS: To examine the effects of an acute dose of ethanol on serum fatty acid ethyl esters (FAEEs) concentration and urinary 5-hydroxytryptophol (5-HTOL)/5-hydroxyindole-3-acetic acid (5-HIAA) ratio. METHODS: Sixteen (14 male, 2 female) heavy alcohol drinkers were tested in a single, 2-day long session. Six participants received 1.5 g/l of ethanol/l of body water (approximately 0.75 g/kg of body weight, low dose group: LD) and 10 participants received 2.0 g/l of ethanol ( approximately 1.0 g/kg of body weight, high dose group: HD) in four divided doses every 20 min. Blood, urine, and breath samples were collected repeatedly over 36 h following the ingestion of ethanol and were analyzed for the presence of FAEE, 5-HTOL/5-HIAA, and ethanol, respectively. Serum gamma-glutamyltransferase (GGT), a marker of chronic ethanol use, was also included. RESULTS: The breath ethanol level peaked approximately 1 h after the last dose, at 95 and 120 mg/dl for the LD and HD groups, respectively. The mean ratio of urinary 5-HTOL/5-HIAA was significantly elevated 5 and 9 h after ethanol administration, but returned to baseline 13 h after ethanol administration. This ratio was twice as high for the HD group compared with the LD group. Serum levels of FAEEs were significantly elevated at 5 h, but not 13 h after ethanol administration. There were no time-dependent changes in serum GGT levels. CONCLUSIONS: Measuring the levels of FAEE and 5-HTOL/5-HIAA ratio provides a convenient method to detect recent, particularly binge-type, ethanol use, but these measures may have limited applicability in detecting ethanol use in traditional clinical trial settings.
Assuntos
Consumo de Bebidas Alcoólicas/sangue , Consumo de Bebidas Alcoólicas/urina , Ácidos Graxos/sangue , Hidroxitriptofol/urina , Adulto , Biomarcadores/sangue , Biomarcadores/urina , Ésteres , Feminino , Humanos , Ácido Hidroxi-Indolacético/urina , Masculino , Fatores de TempoRESUMO
BACKGROUND: Iodine-131 metaiodobenzylguanidine (131I-MIBG) is useful for imaging carcinoid tumors and recently has been applied to the palliative treatment of metastatic carcinoid in small studies. The authors now report their results on the therapeutic utility of high-dose 131I-MIBG treatment in a large group of patients with metastatic carcinoid tumors. METHODS: The authors performed a retrospective review of 98 patients with metastatic carcinoid who were treated at their institution with 131I-MIBG over a 15-year period. Endpoints examined included the World Health Organization criteria for treatment response: symptoms, hormone (5-hydroxyindoleacetic acid [5-HIAA]) production, and clinical tumor response. RESULTS: Patients received a median dose of 401 +/- 202 millicuries (mCi) 131I-MIBG. The median survival after treatment was 2.3 years. Patients who experienced a symptomatic response had improved survival (5.76 years vs. 2.09 years; P < 0.01). For the 56 patients who had 5-HIAA levels monitored, the mean urine 5-HIAA levels decreased significantly after 131I-MIBG treatment (126 +/- 122 ng/mL vs. 91 +/- 125 ng/mL; P < 0.01); however, the patients with reduced 5-HIAA levels did not experience improved survival (4.11 years vs. 3.42 years; P = 0.2). Patients who received an initial 131I-MIBG dose > 400 mCi lived longer than patients who received < 400 mCi (4.69 years vs. 1.86 years; P = 0.05). Radiographic tumor response did not predict survival. Toxicity included pancytopenia, thrombocytopenia, nausea, and emesis. CONCLUSIONS: The current data support 131I-MIBG treatment in select patients with metastatic carcinoid who progress despite optimal medical management. Improved survival was predicted best by symptomatic response to 131I-MIBG treatment, but not by hormone or radiographic response.
Assuntos
3-Iodobenzilguanidina/uso terapêutico , Tumor Carcinoide/radioterapia , Neoplasias Intestinais/radioterapia , Radioisótopos do Iodo/uso terapêutico , 3-Iodobenzilguanidina/efeitos adversos , Adulto , Idoso , Tumor Carcinoide/mortalidade , Tumor Carcinoide/secundário , Feminino , Humanos , Ácido Hidroxi-Indolacético/urina , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
Hepatic artery embolization (HAE) has been utilized for treatment of advanced hepatic carcinoid metastases, with promising symptom palliation and tumor control. Our institution employs transcatheter HAE using Lipiodol/Gelfoam for treatment of carcinoid hepatic metastases, and this report presents our experience with twenty-four patients, examining symptom control, quality-of-life, octreotide dependence, and tumor progression. Twenty-four (11 male, 13 female, mean age = 59.4 +/- 2.5 yr) patients with carcinoid and unresectable hepatic metastases, confirmed by urinary 5-hydroxyindole acetic acid (5-HIAA) measurement and biopsy, were treated with Lipiodol/Gelfoam HAE from 1993-2001. Median follow-up was 35.0 months. Before HAE, 14 patients (58.3%) had malignant carcinoid syndrome, with symptoms quantified using our previously reported Carcinoid Symptom Severity Score, and 13 patients (54.2%) required octreotide for symptom palliation. Following treatment, symptom severity, octreotide dose, and tumor response were measured. Asymptomatic patients did not develop symptoms or require following treatment. Hepatic metastases remained stable (n = 4) or decreased (n = 19) in 23 patients (95.8%). Mean pretreatment Symptom Severity Scores (3.8 +/- 0.2), decreased to 1.4 +/- 0.1 post-treatment (P < 0.00001), with 64.3% of patients becoming asymptomatic. Mean pretreatment octreotide dosages (679.6 +/- 73.0 microg/d), decreased to 262.9 +/- 92.7 microg/d (P = 0.0024) post-treatment, with 46.2% of patients discontinuing octreotide. There were no treatment-related serious complications or deaths. This study demonstrates that Lipiodol/Gelfoam HAE produces excellent control of malignant carcinoid syndrome, allowing patients to decrease or eliminate use of octreotide, while controlling hepatic tumor burden.
Assuntos
Antineoplásicos Hormonais/administração & dosagem , Tumor Carcinoide/terapia , Quimioembolização Terapêutica , Neoplasias Hepáticas/terapia , Octreotida/administração & dosagem , Adulto , Idoso , Tumor Carcinoide/mortalidade , Tumor Carcinoide/fisiopatologia , Tumor Carcinoide/urina , Terapia Combinada , Meios de Contraste/administração & dosagem , Progressão da Doença , Feminino , Esponja de Gelatina Absorvível/administração & dosagem , Hemostáticos/administração & dosagem , Artéria Hepática/efeitos dos fármacos , Humanos , Ácido Hidroxi-Indolacético/urina , Óleo Iodado/administração & dosagem , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/fisiopatologia , Neoplasias Hepáticas/urina , Masculino , Pessoa de Meia-Idade , Análise de SobrevidaRESUMO
A new isocratic HPLC method, employing electrochemical detection, is described for the determination of urinary vanillylmandelic acid, 5-hydroxyindoleacetic acid and homovanillic acid. The main advantages of this technique are: simplicity, simultaneous determination of all analytes, the absence of an extraction procedure, isocratic elution and low cost. The diluted urine is injected onto a C18 reversed phase column. The mobile phase is potassium dihydrogenphosphate buffer containing 1-heptanesulphonic acid, methanol and acetonitrile. The calibration curves are linear from 0.1 to 50 mg/l; the precision data show CV less than 2.36% for within-day assay and less than 2.72% for day-to-day assays. The mean recoveries for supplemented samples are 98.2 to 102.0% for vanillylmandelic acid, 99.6 to 103.9% for 5-hydroxyindoleacetic acid and 98.7 to 102.0% for homovanillic acid. In comparisons of the present method with Radjaipur's extraction method (Radjaipur M. et al., Eur J Clin Chem Clin Biochem 1994; 32:609-13) the slopes for the three analytes were nearly 1, and the confidence region of the intercepts was close to 0. In conclusion the technique seems to be suitable for routine determination of the three analytes, especially for mass screening purposes.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Ácido Homovanílico/urina , Ácido Hidroxi-Indolacético/urina , Ácido Vanilmandélico/urina , Adulto , Cromatografia Líquida de Alta Pressão/normas , Cromatografia Líquida de Alta Pressão/estatística & dados numéricos , Estudos de Avaliação como Assunto , Humanos , Padrões de ReferênciaRESUMO
Serotonin receptor (5-HT3) antagonists provide effective antiemetic therapy in cancer patients receiving emetogenic chemotherapy, such as cisplatin. Animal studies have shown that 5-HT3 receptor antagonists also have antiemetic activity in ipecac-induced emesis. The authors investigated the antiemetic activity of zatosetron maleate, a 5-HT3 receptor antagonist, on ipecac-induced emesis in dogs and healthy men. They also evaluated the effect of ipecac administration on serotonin release and metabolism by measuring urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion in healthy men. In separate randomized, placebo-controlled trials, 20 dogs received zatosetron intravenously and eight healthy men received zatosetron (50 mg) orally, followed by ipecac syrup. In both trials, emetic response to ipecac was recorded, including the number and time of vomits and retches. Zatosetron treatment inhibited and delayed ipecac-induced emesis in both groups. In dogs, zatosetron inhibited ipecac-induced emesis in a dose-dependent manner with a 100-micrograms/kg dose producing complete inhibition. In men, zatosetron administration resulted in fewer emetic episodes after ipecac than had occurred with placebo administration (P = .03); vomiting was completely inhibited by zatosetron. In men, ipecac administration did not affect the urinary 5-HIAA/creatinine ratio (mg/g) or 5-HIAA excretion rate (microgram/hour). Our study demonstrates that zatosetron has similar efficacy on ipecac-induced emesis in healthy men, as has been shown previously with other 5-HT3 receptor antagonists in chemotherapy-induced emesis in cancer patients. We did not observe the increase of urinary 5-HIAA in our study with ipecac-induced emesis, however, as has been described previously in cisplatin-induced emesis.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Benzofuranos/uso terapêutico , Compostos Bicíclicos Heterocíclicos com Pontes , Compostos Bicíclicos com Pontes/uso terapêutico , Ipeca/farmacologia , Antagonistas da Serotonina , Vômito/prevenção & controle , Administração Oral , Adulto , Animais , Benzofuranos/administração & dosagem , Benzofuranos/farmacologia , Compostos Bicíclicos com Pontes/administração & dosagem , Compostos Bicíclicos com Pontes/farmacologia , Cães , Feminino , Humanos , Ácido Hidroxi-Indolacético/urina , Injeções Intravenosas , Ipeca/administração & dosagem , Masculino , Pessoa de Meia-Idade , Vômito/induzido quimicamenteRESUMO
PURPOSE: The authors report their experience treating progressive liver metastases from carcinoid tumor with doxorubicin, iodized oil, and gelatin sponge embolization. MATERIALS AND METHODS: Of 23 patients, 18 had carcinoid syndrome and 19 had elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) levels. Relief of symptoms, changes in 5-HIAA levels, and changes in tumor size could be evaluated in 10, 11, and 17 patients, respectively. RESULTS: Symptomatic response was complete (average duration, 29 months) in 70% and partial in 30% of evaluated patients. Biologic response was complete (average duration, 21 months) in 73%, partial in 18%, and minor in 9% of evaluated patients. Morphologic response was complete in 11%, partial in 24%, and minor in 24% of evaluated patients. Survival after diagnosis of primary tumor, diagnosis of hepatic metastases, and first chemoembolization was 81, 47, and 24 months, respectively. Eight patients were alive at the end of the study. No mortality was related to chemoembolization. CONCLUSION: Chemoembolization is safe and effective for palliation of carcinoid liver metastases.
Assuntos
Tumor Carcinoide/secundário , Tumor Carcinoide/terapia , Quimioembolização Terapêutica , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Adulto , Idoso , Tumor Carcinoide/patologia , Tumor Carcinoide/urina , Cateterismo , Quimioembolização Terapêutica/efeitos adversos , Quimioembolização Terapêutica/métodos , Cisplatino/administração & dosagem , Doxorrubicina/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Seguimentos , Esponja de Gelatina Absorvível/administração & dosagem , Artéria Hepática , Humanos , Ácido Hidroxi-Indolacético/urina , Injeções Intra-Arteriais , Óleo Iodado/administração & dosagem , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/urina , Masculino , Pessoa de Meia-Idade , Mitomicinas/administração & dosagem , Indução de Remissão , Taxa de Sobrevida , Trombose/etiologiaRESUMO
The biochemistry of migraine is complex. Many contradictory or never replicated findings in often small patient groups have been published. The following observations in the platelet-free plasma and urine appear to have some solid basis and will be discussed: 1) systemic derangement of 5-HT metabolism, relevant to the peripheral vascular component of migraine pathophysiology, 2) changes in neuroexcitatory amino acids and magnesium, which may reflect a predisposition of the migraine patient, notably those having attacks with aura, to develop spreading depression, 3) alterations in methionine-enkephalin levels, which may be a useful marker to discriminate between tension headache and migraine, 4) hormonal fluctuations which seem important to set the threshold for an attack, 5) changes of vasoactive peptides in the cranio-vascular circulation, providing the first human evidence that the trigemino-vascular system indeed is relevant in migraine, and 6) catecholaminergic changes suggesting sympathetic overactivity. Finally distinct biochemical differences between patients with migraine without aura and patients with tension headache on one hand, and between patients with migraine with aura and patients with migraine without aura on the other hand will be emphasized. Findings in platelets will be discussed only if they are complementary and supportive to the plasma and urine data.
Assuntos
Transtornos de Enxaqueca/sangue , Ácido Aspártico/sangue , Catecolaminas/sangue , Catecolaminas/urina , Encefalina Metionina/sangue , Estrogênios/metabolismo , Feminino , Glutamatos/sangue , Humanos , Ácido Hidroxi-Indolacético/sangue , Ácido Hidroxi-Indolacético/urina , Masculino , Transtornos de Enxaqueca/urina , Neuropeptídeos/sangue , Serotonina/sangue , Serotonina/urina , beta-Endorfina/sangueRESUMO
Dichlormagnesium-aspartate-hydrochloride was given to 12 patients with mild hypertension in antihypertensive indication at a dose of 10.5 mmol Mg2+/day for 3 months. Blood pressure normalized (from 161.7 +/- 3.4/95.8 +/- 0.8 mmHg to 140.4 +/- 4.0/81.7 +/- 0.9 mmHg, after the third month (p < 0.01). While no changes in Mg2+ concentration in serum were observed in patients with normomagnesaemia, in hypomagnesaemic patients vS-Mg level normalized. Renal excretion of Mg2+ increased: from 3.41 +/- 0.36 before to 5.7 +/- 0.57 mmol Mg2+/24 h after treatment, p < 0.01. Mean plasma serotonin (5HT) concentration showed no changes, although a trend towards an increase in platelet 5HT content was observed. Elevated pre-treatment plasma 5-hydroxyindole acetic acid (5HIAA) concentrations normalized (from 137.29 +/- 20.3 to 78.96 +/- 31.64 nmol/l after the third month, p < 0.05). These findings point to a platelet-stabilizing effect of Mg2+. Fractional excretion of 5HIAA increased (from 1.42 +/- 0.27 to 5.4 +/- 1.22 after treatment, p < 0.01) while mean urinary 5HIAA excretion remained unchanged. It is deduced that a) total body 5HT and 5HIAA production was not affected; b) a long-term supplementation of Mg2+ stimulates the transport of 5HIAA in proximal tubules and, probably, intrarenal 5HIAA synthesis. A functional block in 5HT metabolism under Mg2+ treatment is anticipated. Thus, Mg2+ supplementation has renal and extrarenal effects that are important in treating hypertension and its complications.
Assuntos
Anti-Hipertensivos/uso terapêutico , Ácido Aspártico/uso terapêutico , Hipertensão/tratamento farmacológico , Compostos de Magnésio/uso terapêutico , Serotonina/sangue , Plaquetas/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Combinação de Medicamentos , Feminino , Humanos , Ácido Hidroxi-Indolacético/urina , Hipertensão/sangue , Magnésio/sangue , Masculino , Pessoa de Meia-IdadeRESUMO
High plasma cholesterol levels and plasma lipid peroxidation are associated with atherosclerosis. The effect of excessive dietary tryptophan on plasma lipid peroxidation was studied in rats fed a diet containing soybean oil (control), as well as an atherogenic diet, containing coconut oil and cholesterol. Feeding the atherogenic diet resulted in a 5-fold increment in plasma cholesterol concentration with no significant effect of the tryptophan supplementation. The plasma obtained from the hypercholesterolemic rats exhibited a 67% increased lipid oxidation (measured as thiobarbituric acid reactive substances) in comparison to normocholesterolemic plasma. Dietary tryptophan supplementation increased plasma lipid peroxidation by 9 and 21% in the control and in the hypercholesterolemic animals, respectively. Similarly, the excessive dietary tryptophan enhanced macrophage cholesterol esterification rate by 40 and 38% following cell incubation with the plasma obtained from the control and from the hypercholesterolemic animals, respectively. Since tryptophan is the precursor of serotonin we have measured urine concentration of 5-hydroxyindoleacetic acid (5HIAA), the metabolite of serotonin, and found 22 and 118% elevation in 5HIAA in the tryptophan fed control and hypercholesterolemic rats, respectively. The direct effect of tryptophan and serotonin on in vitro lipid peroxidation was also studied. Low density lipoprotein (LDL) was peroxidized by incubation with copper ions in the presence of tryptophan or serotonin. Serotonin was shown to enhance LDL peroxidation whereas tryptophan had no effect on LDL peroxidation. We conclude that excessive dietary tryptophan may be atherogenic since it enhanced plasma lipid peroxidation in hypercholesterolemic rats and increased macrophage uptake of plasma cholesterol. These effects are probably associated with increased plasma concentration of serotonin following the consumption of a tryptophan supplemented diet.
Assuntos
Peroxidação de Lipídeos/efeitos dos fármacos , Triptofano/farmacologia , Animais , Dieta Aterogênica , Feminino , Ácido Hidroxi-Indolacético/urina , Hipercolesterolemia/sangue , Técnicas In Vitro , Lipídeos/sangue , Lipoproteínas LDL/sangue , Macrófagos/metabolismo , Ratos , Ratos Endogâmicos , Serotonina/farmacologia , Triptofano/administração & dosagemRESUMO
Urinary excretion of monoamine metabolites (noradrenaline-NA, adrenaline-A, 3-methoxy-4-hydroxyphenyl glycol-MHPG, homovanillic acid-HVA, 5-hydroxyindole acetic acid-5 HIAA) was studied in four groups of children as follows: Group I consisting of obese children subjected to caloric restriction and to a short term course of thyroid extract in "low" dosage (1-2 mg/kg bwt), Group II consisting of obese children subjected to diet alone, Group III consisting of children myxedema and subjected to a short term course of thyroid extract given in the "high" dosage (3-5 mg/kg bwt) and Group IV consisting of GH deficient short children having (many of them) thyrotropin deficiency and subjected to a short term course of thyroid extract in "very high" dosage (5-10 mg/bwt). In obese, calorie-restricted children, the previously low mean level of 5 HIAA excretion was further lowered by thyroid extract. In obese children subjected to calorie restriction alone no urinary abnormality was noted. The congenitally hypothyroid patients had low levels of basal 5 HIAA when compared to controls. The degrees of 5-hydroxy tryptamine (5 HT) deficiency in Group III was similar to the obese groups. The thyroid extract course did not influence, at least in short term administration, the low 5 HIAA levels in group III. In GH deficient, short children (group IV) thyroid extract had no significant effect on urinary pattern of monoamine metabolites. A central 5 HT deficiency may tentatively explain the mood disturbances and possibly the other psychic disorders in both the obese and myxedematous patients. The different effects of thyroid extract on 5 HIAA may also witness the differences in the food intake behaviour in these two conditions.
Assuntos
Hipotireoidismo Congênito/urina , Nanismo Hipofisário/urina , Ácido Hidroxi-Indolacético/urina , Hipotireoidismo/urina , Obesidade/urina , Hormônios Tireóideos/uso terapêutico , Adolescente , Criança , Hipotireoidismo Congênito/tratamento farmacológico , Dieta Redutora , Nanismo Hipofisário/tratamento farmacológico , Feminino , Humanos , Hipotireoidismo/tratamento farmacológico , Masculino , Obesidade/tratamento farmacológicoAssuntos
Asma/fisiopatologia , Transtornos de Enxaqueca/fisiopatologia , Modelos Teóricos , Asma/complicações , Asma/tratamento farmacológico , Asma/urina , Pré-Escolar , Feminino , Humanos , Ácido Hidroxi-Indolacético/urina , Masculino , Medicina Tradicional Chinesa , Transtornos de Enxaqueca/complicações , Transtornos de Enxaqueca/tratamento farmacológico , Transtornos de Enxaqueca/urinaRESUMO
The effect of antihypertensive treatment with nitrendipine (10-40 mg/day) on serotonin metabolism and platelet aggregation was investigated in 13 hypertensive patients over a 6-month period. Normalization of elevated blood pressure was achieved [systolic blood pressure (SBP): 167 +/- 4 to 148 +/- 4 mm Hg, p less than 0.01; diastolic blood pressure (DBP): 108 +/- 2 to 95 +/- 3 mm Hg, p less than 0.01; chi +/- SEM before and after the treatment]. The decrease in plasma serotonin (5-HT) levels (354 +/- 140 to 179 +/- 49 nmol/L) and the platelet 5-HT content (9.6 +/- 3.5 to 2.8 +/- 0.9 nmol/10(9) Tro) was observed. Urinary 5-HT and 5-hydroxyindolacetic acid output did not show significant changes. Although the platelet aggregation decreased only moderately, a positive correlation was found between the 5-HT levels in platelet-poor plasma and platelet aggregation indices I (r = 0.699; p less than 0.001). The impaired 5-HT metabolism parameters (high platelet serotonin content and low 5-HT urinary output) in a washout period were normalized under the treatment with nitrendipine. It is concluded that the interaction with serotonergic metabolism could participate in antihypertensive mechanisms of nitrendipine. This effect is of clinical and theoretical importance when taking into account 5-HT atherogenic and mitogenic activity.